Suchergebnisse - "Weinreich, David M"

PubPharm (91)

11

Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies

enthalten in: mBio | 2022

von Hooper, A. | Somersan-Karakaya, S. | McCarthy, S. | +12

12

Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting : a retrospective cohort study using a large claims database

enthalten in: BMJ open | 2022

von Hussein, M. | Wei, W. | Mastey, V. | +6

13

Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19

enthalten in: Infectious diseases and therapy | 2022

von Jalbert, J. | Hussein, M. | Mastey, V. | +9

14

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer : a randomized, controlled, double-blind phase 3 trial

enthalten in: Nature medicine | 2022

von Gogishvili, M. | Melkadze, T. | Makharadze, T. | +23

15

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period : a randomised, double-blind, placebo-controlled trial

enthalten in: The Lancet. Infectious diseases | 2022

von Herman, G. | O'Brien, M. | Forleo-Neto, E. | +127

CommentIn: Lancet Infect Dis. 2022 Oct;22(10):1400-1401. - PMID 35803288

16

Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19

enthalten in: Infectious diseases and therapy | 2022

von Jalbert, J. | Hussein, M. | Mastey, V. | +9

17

Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19

enthalten in: Infectious diseases and therapy | 2022

von Jalbert, J. | Hussein, M. | Mastey, V. | +9

18

Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19

enthalten in: Infectious diseases and therapy | 2022

von Jalbert, J. | Hussein, M. | Mastey, V. | +9

19

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2022

von Isa, F. | Forleo-Neto, E. | Meyer, J. | +28

20

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis : a randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: Lancet (London, England) | 2022

von Paller, A. | Simpson, E. | Siegfried, E. | +56

CommentIn: Lancet. 2022 Sep 17;400(10356):867-869. - PMID 36116468